CONRAD is a biomedical research and development organization dedicated to improving the reproductive health of women, especially in developing countries. They have developed a first-in-class, multipurpose intravaginal ring (IVR) that combines levonorgestrel with tenofovir to provide contraception while preventing against acquisition of Human Immunodeficiency Virus (HIV) and Herpes Simplex Virus (HSV). To bring this novel concept into the clinic, CONRAD needed the support of a contract development and manufacturing organization (CDMO) with specialized expertise in long-acting implant and IVR development. Lubrizol Life Science – Health was able to provide CONRAD with comprehensive support throughout the project from technology transfer to manufacturing. Their experts were proactive and creative in streamlining manufacturing of the product, and they integrated quality control and assurance from the very beginning of the project. As a result, we helped CONRAD to bring a novel, life-changing product to the clinic, and they are committed to helping other organizations develop and commercialize innovative drug eluting devices (DED).
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
Risk-Based Development Supporting Process Qualification for Spray-Dried Dispersion
November 13th 2024Spray drying enables the production of amorphous solid dispersions, allowing efficient scale-up from small screening batches to commercial levels. By leveraging small-scale experiments for process design and qualification, a robust validation strategy can be developed to support flexible, scalable manufacturing for small-molecule drug products. Watch this video to learn more about: